Ischemia-reperfusion injury
===========================

Ischemic heart disease represents a heterogeneous group of pathological conditions characterized by insufficient perfusion of the heart. Coronary artery revascularization and reperfusion of ischemic cardiac tissue is the standard treatment in patients with myocardial infarction. However, reperfusion by itself causes additional tissue injury (termed ischemia-reperfusion injury, IRI) and is associated with a burst of reactive oxygen species (ROS) production and intracellular calcium overload (Garcia-Dorado et al., [@B26]; Kevin et al., [@B39]; Piper et al., [@B60]; Murphy and Steenbergen, [@B54]). Mitochondrial dysfunction plays a central role in cardiomyocyte damage during reperfusion injury (RI). The mitochondrial inner membrane is impermeable to most metabolites and ions; however, in certain stress conditions that can take place during IRI, such as increased calcium concentration, metabolic failure, or oxidative stress, the non-specific mitochondrial permeability transition pore (mPTP) opens in the inner mitochondrial membrane leading to cell death (Halestrap et al., [@B28]). IRI can be limited to some extent by subjecting the heart to short sublethal cycles of ischemia-reperfusion (ischemic preconditioning, IPC) prior to a harmful ischemic insult. Cardiac protection can also be induced by subjecting non-cardiac tissues (e.g., skeletal muscle) to a transient ischemic challenge (remote ischemic preconditioning, RIPC), resulting in the release of cardioprotective soluble factors by the remote ischemic tissue (Murry et al., [@B55]; Kharbanda et al., [@B40]). Given the relevance of oxygen fluctuations during sublethal and lethal ischemia-reperfusion cycles, the molecular pathways driven by the oxygen sensors prolyl hydroxylases (PHDs) and the hypoxia-inducible factors (HIFs) are extensively involved in the mechanisms underlying IPC (Figure [1](#F1){ref-type="fig"}). Moreover, emerging evidence suggests that activation of the PHD-HIF axis in RIPC leads to secretion of HIF-dependent cytoprotectors in peripheral tissues (e.g., skeletal muscle) that could ultimately protect the myocardium from IRI remotely (Figure [1](#F1){ref-type="fig"}). Here we review recent advances and perspectives on the role of these PHD-HIF oxygen-sensing pathways in cardioprotection during IPC and RIPC.

![**Cardioprotection through the PHD-HIF pathway.** Cardiac tolerance against IRI (ischemia reperfusion injury) can be initiated by HIF1α activation locally in the cardiac tissue during IPC (ischemia preconditioning). IPC in the heart leads to cardiac PHD inhibition and subsequent induction of a HIF1α-dependent cardiac metabolic reprogramming, vessel remodeling and activation of the RISK pathway, which ultimately results in reduced cardiac oxidative stress, prevention of mitochondrial permeability transition pore (mPTP) opening and cardiac tissue salvage. The potential role of alternative PHD targets in IPC is indicated. Cardiac tolerance against IRI can be initiated by HIF1α activation at distance in non-cardiac tissue (i.e., hind limb) during RIPC (remote ischemia preconditioning). This remote HIF1α activation releases HIF-dependent soluble cardioprotectors (i.e., IL-10) from the remote tissue into the blood stream. These soluble factors initiate heart protection by activation of RISK pathways to confer cardiac tolerance against IRI, although additionally metabolic reprogramming and vessel remodeling could be potentially involved. The putative role of alternative PHD-dependent targets involved in RIPC is indicated.](fphys-06-00137-g0001){#F1}

The PHD-HIF oxygen-sensing pathway
==================================

The hypoxia-inducible transcription factors (HIF-1α, -2α, -3α) and the oxygen sensors (PHD 1, 2, 3, and factor inhibiting HIF, FIH) are key players in the cellular response to hypoxia. Insufficient oxygen supply to tissues rapidly increases the protein levels of HIFα subunits, which heterodimerize with their HIFß partner to activate transcription of a large number of target genes involved in the adaptive cellular and systemic response to oxygen deprivation (Semenza, [@B65]). HIFα subunits, however, do not sense oxygen directly. A family of oxygen-dependent 2-oxoglutarate dioxygenases that includes PHDs and factor inhibiting HIF (FIH) performs this activity. PHDs and FIH modulate HIF stabilization and transcriptional activation by hydroxylating specific prolyl or asparaginyl residues of HIFα subunits, respectively (Schofield and Ratcliffe, [@B64]). Under normal oxygen tensions, the hydroxylated prolyl residues of HIFα subunits serve as molecular marks for von Hippel-Lindau (VHL) protein, the recognition subunit of an E3 ubiquitin ligase complex, which labels HIFα subunits, through ubiquitination, for subsequent proteasomal degradation (Safran and Kaelin, [@B62]; Schofield and Ratcliffe, [@B64]). Under hypoxia, PHDs and FIH become inactive, resulting in stabilization of HIFα subunits. HIFα subunits then dimerizes with HIFß and translocates to the nucleus to recruit the transcriptional coactivator p300, which is essential for the transcriptional activity of HIFα (Lando et al., [@B43]). As numerous pathological conditions are associated with changes in oxygen tensions, there is a growing interest in understanding the role of the PHD-HIF axis in clinical settings, especially regarding its relevance in IPC- and RIPC-mediated cardioprotection.

Cardiac PHD-HIF oxygen-sensing pathways in IPC
==============================================

IPC is an effective strategy to protect the heart from IRI. This approach requires one or more short sublethal cycles of IR by coronary occlusion to protect the heart against a subsequent longer period of ischemia followed by reperfusion. Emerging evidence suggests that this phenomenon is mediated by the PHD-HIF oxygen-sensing pathway and has been reviewed elsewhere in detail (Fraisl et al., [@B23]). Thus, cardiac upregulation of HIF-1α occurs during IPC (Eckle et al., [@B20]), and partial deficiency or silencing of HIF-1α causes complete loss of IPC-induced protection against myocardial ischemia (Cai et al., [@B8]). Conversely, genetic inactivation or pharmacological inhibition of PHDs, leading to HIF-1α activation, confers cardiac tolerance to IRI (Eckle et al., [@B21], [@B20]; Hyvarinen et al., [@B32]; Holscher et al., [@B31]; Ong et al., [@B57]). Below, we discuss some of the HIF-dependent molecular responses that could be involved in this cardioprotective effect (Figure [1](#F1){ref-type="fig"}).

Reprogramming of cardiac metabolism
-----------------------------------

Under conditions of limiting oxygen, cells reprogram their energy demands by promoting anaerobic metabolism. This response is mediated by HIF-dependent induction of glycolytic enzymes and also genes involved in the attenuation of oxidative metabolism such as pyruvate dehydrogenase kinases (PDK) -1, -3, and -4 (Semenza et al., [@B66]; Kim et al., [@B87]; Papandreou et al., [@B58]; Lu et al., [@B45]; Zhong et al., [@B75]), NDUFA4L2 (Tello et al., [@B70]), and the microRNA-210 (miR210) (Chan et al., [@B10]; Chen et al., [@B11]). Since reperfusion of ischemic tissues can lead to the formation of toxic ROS, triggering cell death, it has been proposed that HIF-dependent reduction of mitochondrial activity might help to counteract cell damage by attenuating the generation of mitochondrial ROS. Along this line, mice deficient for PHD1 present striking resistance to low flow hindlimb ischemia and liver IRI mimicking an IPC scenario (Aragones et al., [@B2]; Schneider et al., [@B63]). Protection seems to be associated with energetic reprogramming toward anaerobic metabolism, ultimately reducing mitochondrial oxygen consumption (Aragones et al., [@B2]; Schneider et al., [@B63]). Recent studies suggest that this anaerobic metabolic switch induced by PHDs could be relevant in cardiac IPC. Indeed, it has been observed that hearts from a PHD2 hypomorphic mouse (PHD2^gt/gt^), with partial reduction of PHD2, display a modest stabilization of HIF factors and a subsequent increase in some, but not all, metabolic genes previously identified as HIF-1α target genes (Hyvarinen et al., [@B32]). Accordingly, the expression of the glucose transporter-1 (Glut-1), phosphofructokinase-1 (Pfk-l), triosephosphate isomerase (Tpi), phosphoglycerate kinase-1 (Pgk-1) and Pdk-1 genes is specifically increased, indicating that these metabolic players could be particularly sensitive to modest elevations of HIF in PHD2^gt/gt^ heart. In line with this transcriptional program, pre-ischemic hearts of PHD2^gt/gt^ hypomorphic mice show enhanced lactate secretion as well as a mild mitochondrial swelling that does not compromise cardiac function. Importantly, when subjected to IR using an *ex vivo* Langendorff perfusion protocol, hearts from PHD2^gt/gt^ mice exhibit improved recovery of cardiac function and an increased amount of ATP (Hyvarinen et al., [@B32]), suggesting that their particular cardiac metabolic adaptation could be responsible for IRI tolerance. Moreover, additional studies in which PHD2 was either inactivated globally (Minamishima et al., [@B50]), or in a cardiomyocyte-restricted manner (Holscher et al., [@B31]), have also demonstrated submaximal HIF activation accompanied with a mild mitochondrial swelling (Minamishima et al., [@B50]) together with increased expression of Glut1, Pgk, Pfkl and Pdk1 genes and protection against myocardial infarction (Holscher et al., [@B31]). A recent study has addressed whether this metabolic reprogramming could be directly involved in HIF-dependent cardiac tolerance to IRI (Ong et al., [@B57]). Accordingly, mice treated with the PHD inhibitor GSK360A have elevated cardiac expression of the glycolytic enzyme hexokinase II, which translocates to mitochondria to alleviate oxidative stress and inhibit mPTP opening (Ong et al., [@B57]). Taken together, these findings suggest that an increased cardiac glycolytic rate upon heart activation of HIF could represent, by itself, a promising cardioprotector mechanism. Nonetheless, it is important to note that a more robust activation of HIF by vhl gene deletion (Lei et al., [@B44]) or simultaneous inactivation of PHD2 and PHD3 (Minamishima et al., [@B50], [@B51]; Holscher et al., [@B31]) leads to a more marked repression of cardiac mitochondrial content, which although undoubtedly prevents the formation of deleterious mitochondrial ROS, also leads to the inevitable impairment of cardiac function (Lei et al., [@B44]; Minamishima et al., [@B51]). Moreover, chronic activation of the HIF-1α/PPARγ axis may contribute to cardiac hypertrophy and heart failure progression by promoting the switch from fatty acid utilization to glycolysis and subsequent lipid accumulation in the heart (Krishnan et al., [@B42]). Globally, these studies suggest that to confer cardioprotection, activation of the PHD-HIF pathway and subsequent metabolic reprogramming in the heart cannot exceed a certain level as disproportionate HIF-activation can lead to heart damage, cardiomegaly and impaired cardiac function (Lei et al., [@B44]; Minamishima et al., [@B50], [@B51]; Holscher et al., [@B31]).

Cardiac endothelial/vascular remodeling
---------------------------------------

Cardiomyocyte-specific PHD2-deficient mice present an increase in heart capillary density, which may positively contribute to cardioprotection after myocardial infarction (Holscher et al., [@B31]). Comparable findings are found in other mouse models associated with stronger cardiac HIF activation (Takeda et al., [@B68]; Lei et al., [@B44]; Minamishima et al., [@B51]; Holscher et al., [@B31]). Notwithstanding the intrinsic cardiac tolerance of PHD2^gt/gt^ mice to reperfusion described in the Langendorff model, endothelial cells have also been suggested to participate in the *in vivo* cardioprotection in these mice upon IRI (Hyvarinen et al., [@B32]). Expression of PHD2 mRNA in PHD2^gt/gt^ transgenic mice is reduced by 76% in cardiac endothelial cells, 77% in cardiac fibroblasts and almost 93% in cardiomyocytes, leading to cardiac stabilization of HIF-1α and HIF-2 α (Kerkela et al., [@B38]). These mice present an overall improved cardiac function measured as an increase in left ventricular (LV) ejection fraction after a 30-min cycle of ischemia by ligation of the left anterior descending (LAD) coronary artery followed by 24 h of reperfusion. Despite the similar capillary density in wild type and PHD2^gt/gt^ mice, the size of the coronary vessels is significantly enlarged and dilated in the transgenic mice, which might be associated with the significantly larger area of the LV perfused during ligation (Kerkela et al., [@B38]). Regarding the potential molecular mechanisms involved in the remodeling of vessels, inhibition of PHD2 in the heart correlates with increased expression of the endothelial genes angiopoietin-2 (Ang2), the angiopoietin receptor Tie-2, Apelin and Apelin receptor, and blockade of Tie2 signaling impairs vessel dilation and greatly abrogates cardiac protection after IRI. Nevertheless, in this study, the AR/LV (area at risk/left ventricle) ratio was not completely reversed in transgenic mice when Tie2 signaling was inhibited, resulting in increased vascular perfusion. Thus, additional vasodilator factors, such as nitric oxide (NO), may participate in the vascular phenotype and cardiac protection of these mice (Kerkela et al., [@B38]).

The reperfusion injury signaling kinase (RISK) pathway
------------------------------------------------------

The RISK pathway comprises a group of pro-survival protein kinases (including Akt and Erk1/2) activated by receptor-dependent and-independent mechanisms, which attenuate mPTP opening and promote cardioprotection during the reperfusion stage of IR (Tsang et al., [@B71]; Park et al., [@B59]; Hausenloy and Yellon, [@B30]). Several studies have identified molecular links between HIF activity and the RISK pathway. Thus, PHD2-deficient hearts, or wild-type hearts subjected to IPC, upregulate key molecules of the adenosine signaling pathway, which are described to promote cardioprotection through the RISK pathway (Hausenloy and Yellon, [@B30]). Some adenosine signaling molecules include the A2B adenosine receptor (A2BAR) and the ecto-5′-nucleotidase CD73, which generates adenosine. Interestingly, CD73 expression is not activated in PHD2^gt/gt^ hypomorphic mice (Hyvarinen et al., [@B32]), suggesting that in this background cardioprotection might be obtained through adenosine-independent signaling, such as for instance the metabolic reprogramming mentioned above. Therefore, it would be pertinent to explore whether additional elements of the RISK pathway are activated in PHD2^gt/gt^ mice, or whether RISK activation requires a stronger cardiac HIF induction. An additional mediator of cardioprotection could be erythropoietin (Epo), the archetype HIF-responsive gene, which we recently found elevated in vhl-deficient hearts (Miro-Murillo et al., [@B52]). Indeed, several reports have shown that Epo protects cardiac tissue during ischemia and IR, particularly by overactivating the serine threonine kinase Akt, as well as through other pathways involving sonic hedgehog (Camici et al., [@B9]; Burger et al., [@B5]; Ueda et al., [@B72]; Ong et al., [@B56]). Thus, it is conceivable that cardiac Epo expression could serve as a local autocrine or paracrine cardioprotector during IPC. In addition, several studies have also shown that cardiac HIF-1α expression can increase sublethal ROS production, resulting in oxidation/inactivation of the protein/lipid phosphatase and tensin homolog (PTEN), which negatively regulates the PI3K/Akt survival pathway (Cai and Semenza, [@B7]; Mocanu and Yellon, [@B53]; Cai et al., [@B8]). Therefore, HIF-1α could overactivate the prosurvival signaling cascades of Akt not only through extracellular soluble factors (e.g., adenosine and Epo), but also by ROS-mediated PTEN inactivation. The mechanisms by which Akt attenuates mPTP opening are still not completely understood, though recent studies suggest that Akt-dependent changes in mitochondrial morphology are required for Akt-dependent cardioprotection against IRI (Ong et al., [@B56],[@B57]).

Nitric oxide signaling
----------------------

Cardiac IPC upregulates the HIF-dependent gene inducible nitric oxide synthase (iNOS) and, importantly, iNOS deficiency abrogates the late phase of IPC (Guo et al., [@B27]). Increased intracellular nitric oxide (NO) as a consequence of endothelial/inducible NOS (eNOS)/iNOS activation plays a central role in cardiac IPC (Jones et al., [@B33]; Jung et al., [@B34]; Divisova et al., [@B18]; Vavrínková et al., [@B73]; Gao et al., [@B24]; Murphy and Steenbergen, [@B54]). At the molecular level, NO-dependent cardioprotection involves stimulation of guanylyl cyclase, which leads to cGMP production and subsequent activation of protein kinase G (PKG). Activated PKG in turn activates mitochondrial pKCε-dependent opening of mito-K~ATP~ channels (Costa et al., [@B12]), resulting in K^+^ influx, matrix alkalinization and subsequent ROS generation (Yao et al., [@B79]; Andrukhiv et al., [@B80]; Costa et al., [@B78]). Regarding the source of ROS, studies in isolated rat mitochondria have shown that intramitochondrial ROS generation is driven by complex I of the electron transport chain (Andrukhiv et al., [@B80]) and an earlier study using intact embryonic chick cardiomyocytes suggested the participation of complex III (Yao et al., [@B79]). Regardless of the mechanisms involved in their generation, mito-K~ATP~ channel-dependent sublethal ROS production is implicated in cardioprotection (Yao et al., [@B79]; Forbes et al., [@B82]; Gross and Lockwood, [@B83]; Shahid et al., [@B81]) because of their ability to activate an additional PKCε pool which ultimately inhibits mPTP opening (Costa et al., [@B78]). Thus, it is possible that PKG and iNOS constitute the molecular link between HIF and sublethal ROS-mediated PTEN inactivation and Akt activation. In fact, iNOS is phosphorylated and activated by Akt, and therefore the iNOS-NO-PKG molecular axis has been positioned as a downstream effector of Akt in IPC (Hausenloy et al., [@B29]). Also, local cardiac NO release may influence vascular tone and thus impact cardiac perfusion upon IRI (Fraisl, [@B22]).

PHD-HIF oxygen sensing pathways in RIPC
=======================================

HIF-dependent soluble factors in RIPC
-------------------------------------

In addition to the phenomenon of IPC described earlier, recent observations indicate that transient and local exposure to hypoxia in certain tissues (limb skeletal muscle, brain, intestine, and kidney) are protective against future ischemic insults to organs and tissues distant from the regional area of initial ischemia, with similar efficacy as local IPC. This unique and innovative treatment approach has been named remote ischemic preconditioning or RIPC (Bolte et al., [@B4]; Randhawa and Jaggi, [@B61]). The potential clinical applications of this endogenous adaptive capacity are enormous and are especially attractive in the setting of clinical interventions to resolve highly prevalent cardiovascular diseases such as coronary obstruction, heart failure or stroke, where tissue reperfusion after an ischemic insult could have devastating consequences (Bolte et al., [@B4]; Randhawa and Jaggi, [@B61]). As a simple, inexpensive and relatively uncomplicated approach to reduce cardiovascular perioperative ischemic damage, there is a growing interest in understanding the molecular mediators (i.e., soluble factors) involved in ischemic protection to improve and develop novel therapeutic strategies. Results from preclinical studies have shown that transient occlusion of cerebral, mesenteric or intestinal arteries, as well as the abdominal aorta or skeletal muscle, promotes cardioprotection against IRI by myocardial preconditioning (Randhawa and Jaggi, [@B61]). In spite of the clinical benefits reported to the date, identification of the protective factors involved in RIPC and how they impact on myocardial survival upon reperfusion remains largely unknown; nevertheless, some novel soluble factors have emerged in the setting of RIPC and recent studies point to a role for the PHD-HIF pathway in RIPC (Figure [1](#F1){ref-type="fig"}). Stabilization of HIF-1α protein in the heart after remote ischemic injury has been confirmed both in basic models (Cai et al., [@B6]; Kalakech et al., [@B35]) and also in human clinical trials (Albrecht et al., [@B1]; Randhawa and Jaggi, [@B61]). The possibility that HIF-1 could control the expression of soluble factors to promote cardioprotection in RIPC was initially tested in muscle tissue using gene delivery of HIF-1 (Czibik et al., [@B14]). Additionally, a positive role for HIF-1 was suggested by experiments showing that HIF-1α-deficient mice completely lose RIPC-induced cardioprotection after transient ligation of the femoral artery (Cai et al., [@B6]). Using a similar experimental approach based on heterozygous HIF-1α heterozygous mice and pharmacological inhibition of HIF with cadmium, Kalakech and colleagues reported that HIF-1 was unnecessary in acute RIPC (Kalakech et al., [@B35]). A potential explanation for these discrepancies could be the subtle technical differences in the hindlimb ischemia protocol to induce RIPC, infarct size determination or the time between the transient ligation of the femoral artery and coronary occlusion. Moreover, despite the dramatic reduction of HIF-1α protein in the limbs of HIF-1α heterozygous mice after RIPC or cadmium treatment, HIF-1α levels were above the control condition. Because all or part of the effects mediated by the secreted component of the RIPC response may be dose dependent, it cannot be ruled out that this minimum amount of HIF-1 may be enough to activate the paracrine-protective mechanism in response to myocardial infarction. Regarding the HIF-dependent soluble factors that could mediate RIPC, Cai and colleagues showed that interleukin-10 (IL-10) is a primary HIF-1α target in murine cardiomyocytes subjected to cyclic hypoxia-reoxygenation. Furthermore, transient femoral ligation increases IL-10 plasma concentration and promotes a subsequent remote activation of cardiac Akt signaling. This effect is inhibited in HIF-1α heterozygous deficient mice, suggesting that IL-10 could be responsible for the activation of Akt pathway in the distant heart and subsequent cardioprotection (Cai et al., [@B6]). In line with the characterization of mechanisms mediating cardioprotection by IL-10, it has been reported that this cytokine can prevent hypertrophic remodeling and improve cardiac function in a model of isoproterenol-induced pressure overload by controling Stat-3 activation and promoting NFκ B inhibition (Verma et al., [@B74]). In addition, the group of Pawan K. Singal has shown that IL-10 promotes Stat-3 activation associated with Akt phosphorylation in cardiomyocytes (Dhingra et al., [@B16]). Furthermore, when IL-10-stimulated cardiomyocytes are treated with the ERK1/2 MAPK inhibitor PD 98059, the cardioprotection mediated by this anti-inflammatory cytokine is lost (Dhingra et al., [@B17]). Also, a recent study has shown that IL-10 activates Toll-like receptor 4 and mediates cardiomyocyte survival in a MyD88-interferon regulatory factor 3 (IRF3)-NFκB dependent manner (Bagchi et al., [@B3]). However, it is important to consider the potential roles of additional HIF-dependent genes in RIPC. Accordingly, hindlimb ischemia also elevates in plasma the stromal cell-derived factor 1 (SDF-1) also known as C-X-C motif chemokine 12 (CXCL12), which mediates cardioprotection through its receptor CXCR4 (Davidson et al., [@B15]). Indeed, this study demonstrated that AMD3100, a highly specific inhibitor of CXCR4, blocked RIPC upon transient femoral ligation, suggesting that IL-10 and SDF1 could act in concert to confer HIF-dependent cardioprotection at a distance.

Finally, cardioprotection after RIPC could be mediated by additional HIF-1α--independent signaling involving soluble factors, such as HIF-2α stabilization and subsequent Epo production (Kapitsinou et al., [@B37]) or NFκB signaling (Kant et al., [@B36]). Along this line, one of the original signals described in IRI models, mito-K~ATP~ channel opening, was found to be a downstream mediator of NFκB activation in a rat model of renal RIPC, with positive effects for cardioprotection (Diwan et al., [@B19]). In terms of pharmacological HIF-PHD inhibition strategies in the setting of RIPC, it is important to appreciate that NFκB signaling is targeted and activated upon PHD inhibition (Cummins et al., [@B13]), potentially contributing to the secretion of inflammatory mediators that might be critical in the evolution of the ischemic insult upon RIPC. Nonetheless, the relative contribution of PHD-dependent but HIF-1-independent pathways in cardiac protection remains poorly explored and warrants further investigation.

Cardiac cell types potentially involved in RIPC
-----------------------------------------------

In addition to cardiomycoytes, the heart is a complex structure composed of many cell types. In the setting of RIPC initiated by extracellular soluble factors, aside from cardiomyocytes, other heart cell types might also respond to cytoprotectors to mediate global cardiac protection. As discussed earlier, the vascular endothelium is an essential element mediating IPC salvage and, in the setting of RIPC, it might also be prudent to determine if some or any of the described cardiac secreted factors (IL-10, SDF1, Epo, etc.) could directly impact endothelial cells to mediate heart protection by regulating the coronary diameter, endothelial permeability or vascular tone. In this respect, the presence of Epo receptors on endothelial cells and the activation of the PI3K/Akt pathway in response to Epo have been previously evaluated (Marzo et al., [@B48]). Additionally, IL-10 has been described to protect against aging or inflammation-mediated endothelial dysfunction (Kinzenbaw et al., [@B41]) and SDF1 has been reported to increase capillary density in a murine model of myocardial infarction (Ziegler et al., [@B77]). Another heart component potentially mediating cardioprotection upon RIPC is the epicardium, the outer most layer of the heart that, during development, contributes to the formation of the coronary vasculature and interstitial cardiac fibroblasts (Martin-Puig et al., [@B47]). Interestingly, upon myocardial infarction, murine epicardial-derived cells (EPDCs) secrete a plethora of paracrine factors mostly related to angiogenesis (Vegfa, Angpt1, Ang, Fgf1, Fgf2, Fgf9, Pdgfa, Pdgfc, Pdgf) among others (Adamts1, Sdf1, Mcp1, and IL-6) and are able to proliferate and migrate toward the infarcted myocardium, giving rise to perivascular fibroblasts and smooth muscle cells (Zhou et al., [@B76]). Remarkably, this paracrine response is associated with a reduction of infarct size and improvement in cardiac function (Zhou et al., [@B76]). Since some of these secreted molecules are HIF targets and others, for instance SDF1, have previously been described as beneficial factors produced upon RIPC, EPDCs could reasonably be mediating part of the cardiac protection provided by RIPC.

Finally, the involvement of soluble mediators such as active cytokines in the cardioprotective effect of RIPC, points to the potential modulation of different aspects of the immune system that could contribute to their beneficial effects. Thus, it will be of special interest to identify the cytokine signature upon RIPC that could modulate immune cell phenotypes such as M1/M2 macrophages and Th17/Treg lymphocyte polarization. Indeed, the participation of NFκB signaling in RIPC cardioprotection (Diwan et al., [@B19]; Kant et al., [@B36]) offers a potential interplay between RIPC, the PHD-HIF pathway and modulation of the immune system.

Concluding remarks and therapeutic opportunities
================================================

Emerging evidence suggests that the PHD-HIF oxygen-sensing pathway induces cardiac intracellular responses (metabolic reprogramming) as well as systemic protective mechanisms initiated by extracellular factors (adenosine, Epo, NO, etc.), which contribute to myocardium salvage during reperfusion. The extracellular component of cardioprotection is strongly supported by the benefits of RIPC that rely on soluble factors released by peripheral ischemic tissues (e.g., IL-10 and SDF1), which subsequently activate cardioprotective RISK pathways in cardiac tissue (Figure [1](#F1){ref-type="fig"}). Thus, in the setting of IPC or RIPC, it might be important firstly to identify novel HIF-dependent soluble cardioprotectors and, secondly, to investigate the impact of these extracellular factors on the coronary endothelium regulating tissue perfusion, or through additional mechanisms, to promote cardioprotection. Importantly, pharmacological inhibition or genetic inactivation of PHD oxygen sensors has been shown to confer ischemic tolerance in heart tissue, which could have clinical impact in countering IR damage. Notwithstanding the potential cardioprotection offered by global HIF activation after systemic PHD pharmacological inhibition, some deleterious side effects may occur when cardiac HIFs are overactivated such as reduced cardiac mitochondrial function or lipid accumulation in the heart. An alternative therapeutic opportunity might be focused on local chemical inhibition of PHDs in remote tissues (e.g., skeletal muscle) in an attempt to mimic the endogenous RIPC response. A caveat to these approaches, however, is that a HIF-dependent cardioprotective program requires some time (perhaps hours), which could limit to some extent its clinical value when the ischemia/reperfusion episode is taking place. A more specific approach could exploit HIF-dependent soluble/secreted factors involved in IPC (adenosine) or RIPC (IL-10, SDF1) as therapies. Indeed, alone or in combination, these factors could be administered in the reperfused cardiac tissue when the occluded coronary artery is reopened. Along this line, the administration of some HIF-dependent soluble factors, such as adenosine or Epo, have been clinically tested in humans although the clinical efficacy has not been fully addressed (Singh et al., [@B67]; Mastromarino et al., [@B49]; Talan and Latini, [@B69]; Garcia-Dorado et al., [@B25]; Lund et al., [@B46]) and further research needs to be conducted in terms of posology and time of administation. A better understanding of the molecular mechanisms linking HIF-secreted factors to cardioprotection and the identification of novel HIF-dependent extracellular molecules will help to overcome these limitations and improve clinical benefits toward salvage of ischemic myocardium.
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